EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, published by Taylor & Francis AS, serves as a pivotal platform for facilitating advanced research and discourse in the fields of Genetics, Molecular Biology, Molecular Medicine, and Pathology. With an impressive Impact Factor and a distinguished status as Q2 in multiple categories, along with a prestigious Q1 ranking in Pathology and Forensic Medicine (2023), this journal continues to attract contributions from leading experts and budding researchers alike. The journal aims to address critical developments in molecular diagnostics, providing insightful reviews that propel the understanding and application of diagnostic techniques in various medical contexts. Accessible to a diverse audience in the academic community, the journal emphasizes the importance of molecular diagnostics in both clinical and laboratory settings, promoting innovative methodologies and comprehensive evaluations of emerging technologies. With ongoing convergence of scientific discovery advancing rapidly from 2001 through 2024, EXPERT REVIEW OF MOLECULAR DIAGNOSTICS remains essential for those committed to furthering the fields of molecular diagnostics and healthcare advancements globally.

Cancer Communications, published by WILEY, is a leading open-access journal that has positioned itself at the forefront of cancer research and oncology since its inception in 2017. With an impressive HIndex reflective of its scholarly impact and recognized in the Q1 category for both Cancer Research and Oncology as of 2023, this journal consistently ranks in the top echelons of its field, specifically at Rank #16/404 and Rank #13/230 in their respective categories on Scopus. Cancer Communications aims to disseminate cutting-edge research findings, innovative methodologies, and significant advancements in cancer treatments, thereby fostering a deeper understanding of oncology among researchers, healthcare professionals, and students. The journal operates under an Open Access model since 2018, ensuring that vital research is accessible to a global audience, thus enhancing collaboration and knowledge sharing necessary to tackle one of the most pressing health challenges of our time. Located in Hoboken, NJ, United States, and with a strong commitment to scientific excellence, Cancer Communications remains an essential resource for anyone engaged in the fight against cancer.

MOLECULAR & CELLULAR PROTEOMICS, published by Elsevier, stands as a premier journal in the fields of Biochemistry, Analytical Chemistry, and Molecular Biology, with a distinguished Q1 ranking reflecting its high impact and contribution to the scientific community. Established in 2002, this journal has consistently provided a platform for the latest research in protein science, merging molecular biology with advanced analytical techniques. With impressive Scopus rankings—41st in Biochemistry and 16th in Analytical Chemistry—it caters to an audience of researchers, professionals, and students eager to explore cutting-edge developments in proteomics. Although currently not designated as open access, the journal aims to foster knowledge dissemination through accessible research content. As it continues to evolve until 2024, MOLECULAR & CELLULAR PROTEOMICS is essential for anyone passionately engaged in the ever-expanding field of proteomics.

The Journal of Molecular Diagnostics is a premier publication in the fields of molecular medicine and pathology, published by Elsevier Science Inc. With an impressive impact factor and recognized as a Q1 journal in both Molecular Medicine and Pathology and Forensic Medicine, this journal is dedicated to advancing the understanding and application of molecular diagnostics in clinical practice. The journal features rigorous peer-reviewed research, comprehensive reviews, and cutting-edge methodologies that highlight novel diagnostic tests and biomarkers. Researchers, professionals, and students in the biomedical sciences are invited to explore its diverse array of articles and contribute to a growing body of knowledge critical for innovation in healthcare delivery. Located in the Netherlands, the journal has secure its position among the top-tier journals with its recent Scopus ranking of 20th out of 208 in Medicine Pathology and Forensic Medicine, reflecting a strong percentile ranking of 90th. With coverage spanning from 1999 to 2024, the Journal of Molecular Diagnostics remains a vital resource for anyone committed to the future of molecular research and diagnostics.

Cancer Biomarkers is a leading journal in the field of cancer research, aimed at the exploration and identification of novel biomarkers for cancer detection, prognosis, and therapy. Published by IOS PRESS in the Netherlands, this journal serves as a pivotal resource for those engaged in oncology, genetics, and molecular biology, facilitating access to cutting-edge research and advancements within these disciplines. In its ongoing mission since 2005, the journal has become an essential reference point, currently occupying a Q3 category in Cancer Research, Genetics, and Oncology, and a Q2 category in miscellaneous Medicine fields. With its commitment to high-quality peer-reviewed articles, Cancer Biomarkers satisfies the intellectual appetite of researchers, clinicians, and students alike, contributing significantly to the ever-evolving landscape of cancer biomarker discovery and application. Though currently not available as Open Access, the journal maintains a robust presence in academic circles, underscored by respectable Scopus rankings across relevant categories.

The Journal of Cancer Research and Therapeutics is a prominent peer-reviewed platform dedicated to advancing scientific knowledge in the fields of oncology, radiology, and therapeutic interventions. Published by Wolters Kluwer Medknow Publications in India, this journal has been an essential resource for researchers and professionals since its inception in 2005, with a convergence of findings through to 2024. Although classified within the Q3 quartile across multiple relevant categories in the 2023 rankings, the journal maintains a significant impact in the fields of medicine, particularly in oncology and radiology, as evidenced by its Scopus rankings. The journal aims to disseminate high-quality research, case studies, and clinical trials that contribute to understanding and improving cancer treatments and patient care. With its accessibility to a global audience, the Journal of Cancer Research and Therapeutics plays a pivotal role in fostering dialogue and collaboration among researchers and healthcare professionals dedicated to combating cancer.

The Journal of Pathology Clinical Research is a prestigious academic platform published by WILEY, dedicated to advancing the field of pathology and forensic medicine. Since its inception in 2015, this Open Access journal has championed the dissemination of cutting-edge research relevant to both clinical practice and laboratory science, allowing for greater visibility and accessibility to researchers, professionals, and students worldwide. With a robust Q1 ranking in the Pathology and Forensic Medicine category for 2023, it stands as a critical resource for those seeking to stay at the forefront of the field, currently positioned at rank #29 out of 208 according to Scopus metrics, placing it in the 86th percentile. The journal's commitment to high-quality peer-reviewed articles fosters an environment of scholarly exchange that is essential for innovation and professional growth in pathology and forensic studies. Researchers and practitioners alike are encouraged to contribute and engage with a community dedicated to excellence in clinical research.

Wspolczesna Onkologia - Contemporary Oncology is a leading open-access journal dedicated to the field of oncology and radiology, published by TERMEDIA PUBLISHING HOUSE LTD since 1999. With its ISSN 1428-2526 and E-ISSN 1897-4309, the journal has established a prominent place in scholarly publishing, contributing significantly to the advancement of cancer research and treatment modalities. Located in Poznań, Poland, it operates within a framework of high academic standards, currently holding a Q3 quartile ranking in Oncology and Q2 in Radiology, Nuclear Medicine, and Imaging for the year 2023. The journal serves as a valuable resource for researchers, medical professionals, and students alike, providing a platform for innovative studies and reviews that drive the clinical application of oncological practices. With its commitment to open access, Wspolczesna Onkologia allows for widespread dissemination of knowledge, ensuring that cutting-edge research is accessible to a global audience, thus bridging gaps in cancer care and fostering collaborative advancements in the field.

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

MOLECULAR CANCER RESEARCH, published by the American Association for Cancer Research, stands as a pivotal journal in the fields of cancer research, molecular biology, and oncology. With an impressive impact factor and recognized as a Q1 journal in its respective categories for 2023, it serves as an essential resource for researchers, professionals, and students aimed at advancing our understanding of cancer mechanisms and therapies. The journal, identified by the ISSN 1541-7786 and E-ISSN 1557-3125, provides a platform for cutting-edge research and clinical applications, emphasizing innovation and collaboration within the scientific community. With its focus on high-quality, peer-reviewed articles, MOLECULAR CANCER RESEARCH is vital for anyone looking to stay abreast of significant advancements in cancer biology and treatment strategies. For more details and to access the journal's content, please visit the publisher's link.